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Summary. In eight patients with uncomplicated non in- 
sulin dependent diabetes mellitus, serum insulin levels, 
serum C-peptide levels and blood glucose levels were 
measured before and after oral administration of gliben- 
clamide 0.1 mg/kg body weight and a test meal, or after a 
test meal alone. 
The rise in serum insulin levels persisted longer after 
glibenclamide. The initial rise in serum insulin was of the 
same magnitude inboth situations, as was the rise in serum 
C-peptide levels during the entire 5 h study. 
It is concluded that glibenclamide is able to maintain a
more protonged increase in serum insulin levels by inhi- 
biting the degradation of insulin in the vascular endothe- 
lial cells of the liver. The inhibition contributes to the 
blood glucose lowering effect of glibenclamide. 
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Sulphonylureas were serendipitously discovered to have 
a glucose-lowering effect in the course of clinical studies 
on the treatment of typhoid fever [1]. It soon became 
clear that they had both a blood glucose level lowering 
effect as well as an insulin-releasing effect [2]. Sulphonyl- 
ureas increase the number of the insulin receptors [3]. 
Another mechanism which might explain the extrapan- 
creatic effect of sulphonylureas in lowering blood glu- 
cose, has only relative recently been discovered. Insulin 
is secreted by the pancreas into the portal vein and it 
must pass the liver and the endothelial surface of its vas- 
cular bed before reaching the systemic irculation. De- 
creasing insulin breakdown by the endothelial cells could 
result in an 'insulin-saving' effect. The potential 'insulin- 
saving' effect of the sulphonylurea glibenclamide has 
been studied by comparing insulin C peptide and blood 
glucose levels before and after B-cell stimulation by a 
meal alone, or a combined meal and glibenclamide, in
8 patients with mild non-insulin dependant diabetes mel- 
litus. 
Patients and methods 
There eight patients uffering from uncomplicated non insulin de- 
pendant diabetes mellitus in the study (mean age 56 (6) y; 6 m and 
2 f; height 169 (5 cm); weight 71 (5) kg. The mean duration of the in 
diabetes was 5 (1) y. None of the patients was taking any medicine. 
They all had normal renal and hepatic function, none was suffering 
from malabsorption, and none had any other endocrine disorder. 
Glibenclamide t st: Before and 30, 60, 90, 120, 180 and 360 min 
after oral glibenclamide 0.1 mg.kg -1 body weight blood samples 
were taken for measurement of serum insulin and C-peptide levels 
and blood glucose. The patients ate a standardized meal [12] directly 
after taking the dose of glibenclamide; it consisted oftwo 50 g boiled 
eggs, 60 g white, untoasted, sliced bread covered with 12 g butter, 
and 200 ml fresh, squeezed orange juice supplemented with 10 g 
sugar (beet saccharose). It contained 18 g proteins, 22 g lipids and 
60 g carbohydrates and presented about 500 kcaI. After about one 
week each patient underwent a second test in which the same stand- 
ardized meal was eaten but without he dose of glibenclamide. In the 
first four patients the glibenclamide test was performed first. The pa- 
tients at comfortably inan armchair during the test. 
Insulin assay: Serum insulin levels were measured by radioimmu- 
noassay using a guinea pig antiporcine insulin antibody and charcoal 
dextran separation ofbound - and free J25I-labelled insulin. The pre- 
par insulin standard was the First International Reference Prepara- 
tion. 
C-peptide assay Serum C-peptide levels were measured with a 
Novo C-peptide kit (Novo Institute Denmark). Statistical nalysis. 
Results are expressed as mean with (SEM). Statistical significance 
was analysed by Student's t-test for paired ata. 
Results 
The serum insulin and serum C-peptide levels and blood 
glucose before and after a standardized meal alone and 
after a standardized meal + glibenclamide are shown in 
Fig. 1. Basal values of blood glucose, insulin and C-peptide 
before either a standardized meal alone or a standardized 
meal + glibenclamide were not significantly different. 
The standardized meal alone was followed by a rapid, 
marked increase in blood glucose levels, reaching amaxi- 
mum of 16.8 (1.3) mmol. 1- ~ at 90 min, and associated with 
a delayed and blunted response in plasma insulin - maxi- 
mum of 18.1 (0.8)gU.m1-1) at 120min. Blood glucose 
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there was a significantly by smaller increase in blood glu- 
cose than after the standardized meal alone: 2450 (158) 
versus 3620 (159)retool.1 -~(P < 0.001). The increase in 
serum insulin levels after the standardized meal + gliben- 
clamide was significantly greater (13020 (2420) versus 
5200 (1410)gU.min.ml-~; P<0.001). Although at 
120 min serum C-peptide levels after a standardized meal 
+ glibenclamide were significantly higher than after the 
meal alone, the change in serum C-peptide level (as the 
AUC) was not significantly different in the two situations 
(419 (48) versus 381 (45) pmol. min. ml- 1). 
Discussion 
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Fig.1. Mean serum insulin, C-peptide and blood glucose leveIs in 
eight patients with from non-insulin dependent diabetes mellitus, 
after a test meal alone [--], and a test meal with glibenclamide 
0.1 mg/kg body weight [---]. Error bars indicate SEM 
*=P<0.05 **=P<0.01 ***=P<0.001 
had returned to its basal value at the end of the test, 
whereas erum insulin and serum C-peptide levels were 
still elevated at that time. 
After a standardized meal + glibenclamide the rise in 
blood glucose was markedly truncated: maximum of 12.9 
(1.1) mmol- 1-1 at 30 min. After 30 min, the blood glucose 
level rapidly decreased to a minimum at 300 min of 8.1 
(1.0) mmol.1-1. The rise in serum insulin levels was 
steeper and reached a level three-times higher than after 
the standardized meal alone: maximum at 60 rain to 
90 min, with a steady state level of 56 U- ml 1. 
In contrast, the increase in serum C-peptide levels 
measured after the standardized meal + glibenclamide 
was almost identical to that after the me al alone; the sole 
exception was at 120 min - 1.3 (1.0) pmol. 1-1. 
The AUC (0-300 min) were calculated for the three 
blood levels. After a standardized meal + glibenclamide 
The liver plays a central role in the catabolism of insulin, 
removing approximately 50-70% of the hormone se- 
creted by the pancreas from the portal vein before it 
reaches the systemic irculation [4]. The 'insulin-saving' 
effect of glibenclamide in 8 patients with non insulin de- 
pendent diabetes was examined here. The 'insulin-saving' 
effect was taken to mean inhibition of the breakdown of 
insulin by the endothelial cells of the liver. The B-cell mass 
of the pancreas was stimulated by use of glibenclamide as 
a secretagogue. Proinsulin is the product of biosynthesis in
the B-cells [5]. Proinsulin, excreted by B-cells, is split into 
insulin and C-peptide in equimolar concentrations [6]. 
Therefore the C-peptide concentration is also an indicator 
of B-cell function. The vast majority of C-peptide is cata- 
bolized by the kidney [7] and not by the liver. Hepatic ex- 
traction of C-peptide is about 50% lower than that of in- 
sulin [8]. It has been shown that vascular endothelial cells 
of the liver actively bind and degrade insulin [9]. The in- 
sulin - C-peptide ratio is dependent upon the interaction 
of many factors related to the secretion, metabolism, dis- 
tribution and half-life (insulin 4 min and proinsulin 
30 rain; [10]) of insulin and proinsulin. In the study two se- 
cretagogues for insulin secretion were employed. Patients 
received astandardized meal alone as a secretagogue, or a 
standardized meal together with glibenclamide. Both 
tests provoked an equal increase in serum C-peptide le- 
vels. In both tests in the first 30 min, there was an equal 
rise in serum insulin level, but from then on wards serum 
insulin levels still rose in patients also given glibencla- 
mide. When the patients did not take glibenclamide, 
serum insulin levels fell after 30 rain. 
Although the rise in serum C-peptide levels after a 
standardized meal + glibenclamide appears higher than 
after a standardized meal alone, no significant difference 
was found when measuring the AUCs. Considering the 
difference found in serum insulin levels in the two tests, 
and the fact that B-cells secrete C-peptide and insulin in 
equimolar concentrations, it appears that glibenclamide 
can raise insulin levels not only by augmentation f secre- 
tion, but also by a selective decrease in the catabolism of 
insulin in the liver. Inhibition of the degradation ofinsulin 
in the liver could be the explanation for the slower fall in 
insulin levels in diabetic patients on glibenclamide. A simi- 
lar conclusion was drawn by Almer et al. [11] and Sheen 
et al. [12], using glipizide as the sulphonylurea derivative, 
and by Marshall et al. [13], using other sulphonylureas. 
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It is suggested that the most important mechanism for 
the catabolism of insulin is receptor-l inked degradation. 
After a therapeutic dose it is possible that the antidiabe- 
togenic effect of glibenclamide is also achieved by inhibi- 
tion of the receptor-l inked insulin degradation system of 
the endothelial cells of the liver. In doing so glibenclamide 
would be inhibiting the catabolism of insulin in the liver. 
Such an action would have a profound effect upon the 
overal handling of insulin by the body. 
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